Eagle Genomics
Developing life sciences smart data management and analysis solutions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | $4.0m Valuation: $100m | Early VC | |
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 12 % | 7 % | (25 %) | 36 % | 2 % | 79 % | 80 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (69 %) | (104 %) | (144 %) | (178 %) | (352 %) | (200 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (43 %) | (58 %) | (129 %) | (183 %) | (183 %) | (205 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 135 % | 63 % | - | - | - | - | - |
Source: Company filings or news article, Dealroom estimates
Related Content
Eagle Genomics is a pioneering company operating at the intersection of life sciences and data science. The company specializes in leveraging big data to unlock the potential of the microbiome, which is the community of microorganisms living in various environments, including the human body. By utilizing advanced data analytics and artificial intelligence, Eagle Genomics helps its clients understand and harness the power of microbiomes to drive innovation and improve outcomes in health, agriculture, and other sectors.
The company primarily serves clients in the life sciences industry, including biotechnology firms, pharmaceutical companies, and agricultural businesses. One notable client is Cargill, a global food corporation, with whom Eagle Genomics has entered into a multi-year platform engagement. This partnership underscores the company's ability to deliver scalable and impactful solutions.
Eagle Genomics operates in the rapidly growing market of microbiome research and data analytics. This market is driven by the increasing recognition of the microbiome's role in health and disease, as well as its potential applications in agriculture and other industries.
The business model of Eagle Genomics revolves around its proprietary platform, which integrates and analyzes complex microbiome data. Clients subscribe to this platform to gain insights that can drive their research and development efforts. The company generates revenue through these subscription fees, as well as through bespoke data analysis services and long-term partnerships.
In summary, Eagle Genomics is a data-driven company that empowers life sciences organizations to explore and exploit the microbiome's potential. By providing cutting-edge analytics and insights, the company helps its clients innovate and achieve better outcomes.
Keywords: microbiome, data analytics, life sciences, big data, AI, biotechnology, agriculture, health, platform, innovation.